

Patrick J Morris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8320619/publications.pdf>

Version: 2024-02-01

34
papers

4,193
citations

279487

23
h-index

360668

35
g-index

39
all docs

39
docs citations

39
times ranked

5477
citing authors

#	ARTICLE	IF	CITATIONS
1	NMDAR inhibition-independent antidepressant actions of ketamine metabolites. <i>Nature</i> , 2016, 533, 481-486.	13.7	1,246
2	Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. <i>Pharmacological Reviews</i> , 2018, 70, 621-660.	7.1	723
3	Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. <i>Nature</i> , 2017, 549, 533-537.	13.7	350
4	Palladium-Catalyzed Diastereo- and Enantioselective Synthesis of Substituted Cyclopentanes through a Dynamic Kinetic Asymmetric Formal [3+2]-Cycloaddition of Vinyl Cyclopropanes and Alkylidene Azlactones. <i>Angewandte Chemie - International Edition</i> , 2011, 50, 6167-6170.	7.2	207
5	Palladium-Catalyzed Diastereo- and Enantioselective Formal [3 + 2]-Cycloadditions of Substituted Vinylcyclopropanes. <i>Journal of the American Chemical Society</i> , 2012, 134, 17823-17831.	6.6	170
6	Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. <i>Molecular Psychiatry</i> , 2021, 26, 6704-6722.	4.1	139
7	Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	129
8	High-potency ligands for DREADD imaging and activation in rodents and monkeys. <i>Nature Communications</i> , 2019, 10, 4627.	5.8	128
9	Antidepressant-relevant concentrations of the ketamine metabolite (2 <i>R</i> ,6 <i>R</i>)-hydroxynorketamine in the rat. <i>Journal of Clinical Investigation</i> , 2019, 129, 1160-1169.	3.3	120
10	(2 <i>R</i> ,6 <i>R</i>)-hydroxynorketamine exerts mGlu ₂ receptor-dependent antidepressant actions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 6441-6450.	3.3	112
11	The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005540.	1.3	97
12	Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects. <i>Psychopharmacology</i> , 2018, 235, 3017-3030.	1.5	81
13	Organophosphorus Flame Retardants Inhibit Specific Liver Carboxylesterases and Cause Serum Hypertriglyceridemia. <i>ACS Chemical Biology</i> , 2014, 9, 1097-1103.	1.6	76
14	Synthesis and <i>N</i> -Methyl-D-aspartate (NMDA) Receptor Activity of Ketamine Metabolites. <i>Organic Letters</i> , 2017, 19, 4572-4575.	2.4	64
15	(<i>R</i>)-Ketamine exerts antidepressant actions partly via conversion to (<i>2R,6R</i>)-hydroxynorketamine, while causing adverse effects at subanaesthetic doses. <i>British Journal of Pharmacology</i> , 2019, 176, 2573-2592.	2.7	61
16	Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications. <i>Pharmacological Reviews</i> , 2021, 73, 763-791.	7.1	54
17	Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures. <i>Journal of Infectious Diseases</i> , 2018, 218, S672-S678.	1.9	49
18	Metabolic Profiling Reveals PAFAH1B3 as a Critical Driver of Breast Cancer Pathogenicity. <i>Chemistry and Biology</i> , 2014, 21, 831-840.	6.2	44

#	ARTICLE	IF	CITATIONS
19	Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2 <i>R</i> ,6 <i>R</i>)-hydroxynorketamine. <i>Journal of Psychopharmacology</i> , 2019, 33, 12-24.	2.0	41
20	Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 1203-1207.	1.3	39
21	Multidimensional Profiling Platforms Reveal Metabolic Dysregulation Caused by Organophosphorus Pesticides. <i>ACS Chemical Biology</i> , 2014, 9, 423-432.	1.6	31
22	Zanos et al. reply. <i>Nature</i> , 2017, 546, E4-E5.	13.7	29
23	Reply to: Antidepressant Actions of Ketamine Versus Hydroxynorketamine. <i>Biological Psychiatry</i> , 2017, 81, e69-e71.	0.7	22
24	miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. <i>Journal of Experimental Medicine</i> , 2018, 215, 2115-2136.	4.2	20
25	A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2 <i>R</i> ,6 <i>R</i>)-hydroxynorketamine and MK-801. <i>Neurotoxicology and Teratology</i> , 2021, 87, 106993.	1.2	15
26	Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (2 <i>S</i>)- and (5 <i>R</i>)-Methyl-(2 <i>R</i> ,6 <i>R</i>)-hydroxynorketamines. <i>ACS Chemical Neuroscience</i> , 2022, 13, 510-523.	1.7	15
27	Target deconvolution studies of (2 <i>R</i> ,6 <i>R</i>)-hydroxynorketamine: an elusive search. <i>Molecular Psychiatry</i> , 2022, 27, 4144-4156.	4.1	15
28	Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo. <i>Microorganisms</i> , 2021, 9, 566.	1.6	13
29	Chemical Genetics Screening Reveals KIAA1363 as a Cytokine-Lowering Target. <i>ACS Chemical Biology</i> , 2014, 9, 2905-2913.	1.6	9
30	Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration. <i>Translational Psychiatry</i> , 2022, 12, 179.	2.4	8
31	¹⁸ F-labeled radiotracers for in vivo imaging of DREADD with positron emission tomography. <i>European Journal of Medicinal Chemistry</i> , 2021, 213, 113047.	2.6	7
32	Apilimod. <i>IUCrData</i> , 2017, 2, .	0.1	4
33	Time will tell. Reply to "Comments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al." by Chen et al.. <i>Molecular Psychiatry</i> , 2022, 27, 1863-1865.	4.1	3
34	The show must go on. Reply to "Distinct functions of S-ketamine and R-ketamine in mediating biobehavioral processes of drug dependency: comments on Bonaventura et al." by Insop Shim. <i>Molecular Psychiatry</i> , 0, , .	4.1	0